CA2303663A1 - Expression de genes des cellules souches hematopoietiques dans des conditions hischaemique - Google Patents

Expression de genes des cellules souches hematopoietiques dans des conditions hischaemique Download PDF

Info

Publication number
CA2303663A1
CA2303663A1 CA002303663A CA2303663A CA2303663A1 CA 2303663 A1 CA2303663 A1 CA 2303663A1 CA 002303663 A CA002303663 A CA 002303663A CA 2303663 A CA2303663 A CA 2303663A CA 2303663 A1 CA2303663 A1 CA 2303663A1
Authority
CA
Canada
Prior art keywords
vector
cell
cells
gene
vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002303663A
Other languages
English (en)
Inventor
Claire Elizabeth Lewis
Katie Mary Binley
Christopher Robert Bebbington
Michael Stuart Naylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9720216.2A external-priority patent/GB9720216D0/en
Priority claimed from GBGB9720465.5A external-priority patent/GB9720465D0/en
Application filed by Individual filed Critical Individual
Publication of CA2303663A1 publication Critical patent/CA2303663A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne un vecteur rétroviral. Le vecteur rétroviral comprend un site donneur d'épissure fonctionnelle et un site accepteur d'épissure fonctionnelle; le site donneur d'épissure fonctionnelle et le site accepteur d'épissure fonctionnelle flanquent une première séquence nucléotidique intéressante ("NOI"); le site donneur d'épissure fonctionnelle se trouve en amont du site accepteur d'épissure fonctionnelle et le vecteur rétroviral est dérivé d'un pro-vecteur rétroviral; le pro-vecteur rétroviral comprend une première séquence nucléotidique ("NS") capable de produire le site donneur d'épissure fonctionnelle et une deuxième NS capable de produire le site accepteur d'épissure fonctionnelle; et la première NS se trouve en aval de la deuxième NS; de sorte que le vecteur rétroviral est le résultat d'une transcription inverse du pro-vecteur rétroviral.
CA002303663A 1997-09-23 1998-09-23 Expression de genes des cellules souches hematopoietiques dans des conditions hischaemique Abandoned CA2303663A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9720216.2 1997-09-23
GBGB9720216.2A GB9720216D0 (en) 1997-09-23 1997-09-23 Delivery of therapeutic genes to haematopoietic stem cells
GBGB9720465.5A GB9720465D0 (en) 1997-09-25 1997-09-25 Dual-virus vectors
GB9720465.5 1997-09-25
PCT/GB1998/002885 WO1999015684A2 (fr) 1997-09-23 1998-09-23 Methode

Publications (1)

Publication Number Publication Date
CA2303663A1 true CA2303663A1 (fr) 1999-04-01

Family

ID=26312300

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002303663A Abandoned CA2303663A1 (fr) 1997-09-23 1998-09-23 Expression de genes des cellules souches hematopoietiques dans des conditions hischaemique

Country Status (11)

Country Link
EP (1) EP1017838A2 (fr)
JP (1) JP2001517453A (fr)
KR (1) KR20010052076A (fr)
CN (1) CN1303442A (fr)
AU (1) AU747609B2 (fr)
CA (1) CA2303663A1 (fr)
GB (1) GB2345063B (fr)
IL (1) IL134897A0 (fr)
NO (1) NO20001487L (fr)
NZ (1) NZ503318A (fr)
WO (1) WO1999015684A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420963T1 (de) * 1998-09-23 2009-01-15 Oxford Biomedica Ltd Polynucleotidkonstrukte und ihre verwendungen
CA2351622A1 (fr) 1998-11-18 2000-05-25 Oxford Biomedica (Uk) Limited Polypeptide
GB0400443D0 (en) 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
US7148035B1 (en) 1998-11-18 2006-12-12 Oxford Biomedica (Uk) Limited Polypeptide
GB9906615D0 (en) * 1999-03-22 1999-05-19 Oxford Biomedica Ltd Vector
US6849454B2 (en) 2000-03-07 2005-02-01 St. Jude Children's Research Hospital Highly efficient gene transfer into human repopulating stem cells by RD114 pseudotyped retroviral vector particles
AU2001240078A1 (en) * 2000-03-07 2001-09-17 St. Jude Children's Research Hospital Highly efficient gene transfer into human repopulating stem cells by rd114 pseudotyped retroviral vector particles
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
GB0024550D0 (fr) * 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US6573092B1 (en) * 2000-10-10 2003-06-03 Genvec, Inc. Method of preparing a eukaryotic viral vector
GB0203419D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
GB0203420D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
AU2004242614B2 (en) 2003-05-30 2011-09-22 Merus N.V. Fab library for the preparation of anti vegf and anti rabies virus fabs
JP4572320B2 (ja) * 2004-02-23 2010-11-04 財団法人大阪産業振興機構 組換えヒト細胞、ならびにその組換えヒト細胞を用いてヒト薬物代謝酵素の誘導および薬物代謝の少なくとも一方を評価する方法
EP1888634A2 (fr) 2005-05-13 2008-02-20 Oxford Biomedica (UK) Limited Antigène peptide mhc classe i et ii dérivé d'une tumeur antigène 5t4
EP2669368B1 (fr) 2006-05-17 2016-08-03 Cognate Therapeutics, Inc. Isolation et purification de cellules souches hématopoïétiques à partir d'aspirâts de liposuccion
EA035344B1 (ru) 2012-04-20 2020-05-29 Мерюс Н.В. Способ получения двух антител из одной клетки-хозяина
WO2017108931A1 (fr) * 2015-12-22 2017-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Systèmes de vecteurs aav de recombinaison doubles hybrides améliorés pour la thérapie génique
CN113699146B (zh) * 2020-05-22 2024-07-02 深圳市深研生物科技有限公司 启动元件及包含其的逆转录病毒基因组转录盒和载体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06509578A (ja) * 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
FR2709309B1 (fr) * 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
GB9402857D0 (en) * 1994-02-15 1994-04-06 Isis Innovation Targeting gene therapy
WO1995029704A1 (fr) * 1994-04-28 1995-11-09 Scott Freeman Lignees cellulaires obtenues par migration in vivo et par fusion avec des cellules autoimmune
US5834306A (en) * 1994-12-23 1998-11-10 Sri International Tissue specific hypoxia regulated therapeutic constructs
NZ334312A (en) * 1996-10-09 2000-10-27 Oxford Biomedica Ltd Use of mononuclear phagocytes and a binding agent in therapeutic drug delivery

Also Published As

Publication number Publication date
NZ503318A (en) 2001-11-30
KR20010052076A (ko) 2001-06-25
CN1303442A (zh) 2001-07-11
WO1999015684A8 (fr) 1999-08-12
EP1017838A2 (fr) 2000-07-12
NO20001487D0 (no) 2000-03-22
AU747609B2 (en) 2002-05-16
WO1999015684A3 (fr) 1999-06-10
JP2001517453A (ja) 2001-10-09
NO20001487L (no) 2000-05-23
WO1999015684A2 (fr) 1999-04-01
GB0006993D0 (en) 2000-05-10
WO1999015684A9 (fr) 1999-09-16
AU9356298A (en) 1999-04-12
GB2345063B (en) 2002-07-24
IL134897A0 (en) 2001-05-20
GB2345063A (en) 2000-06-28

Similar Documents

Publication Publication Date Title
AU747609B2 (en) Expression of genes in hematopoietic stem cells in hischaemic conditions
US7303910B2 (en) Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site
EP1504108B1 (fr) Vecteur lentivirale
US8501464B2 (en) Lentiviral vectors carrying synthetic bi-directional promoters and uses thereof
US7056699B2 (en) Lentiviral LTR-deleted vector
US20040234505A1 (en) Polynucleotide constructs and uses thereof
EP1218528A1 (fr) Cellule de production pour la production de vecteurs retroviraux
US20050260164A1 (en) Gene regulation with aptamer and modulator complexes for gene therapy
US20030113898A1 (en) Methods for producing high titre vectors and compositions used in such methods
US20050191747A1 (en) Recombinant bovine immunodeficiency virus based gene transfer system
EP1115877B1 (fr) Produits de recombinaison polynucleotidiques et leurs utilisations
US9932597B2 (en) Vectors for transgene expression
AU3312800A (en) Retroviral vectors comprising functional and non-functional splice donor and splice acceptor sites
CA2343324A1 (fr) Produits de recombinaison polynucleotidiques et leurs utilisations
ZA200101494B (en) Polynucleotide contructs and uses therof.

Legal Events

Date Code Title Description
FZDE Discontinued